Industry
Medical - Diagnostics & Research
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
April 05, 2024 | 4:39 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 11:59 am
Portfolio Pulse from Avi Kapoor
March 11, 2024 | 5:41 pm
Portfolio Pulse from Benzinga Insights
March 11, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Insights
March 06, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
March 06, 2024 | 3:56 pm
Portfolio Pulse from Benzinga Newsdesk
March 06, 2024 | 3:02 pm
Portfolio Pulse from Benzinga Newsdesk
March 06, 2024 | 2:57 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.